Business
Novo Nordisk: Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China
UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo NordiskIn a placebo-controlled phase 2 trial in Chinese people with overweight or obesity, UBT251 led to a statistically significant mean weight loss of up to 19.7% after 24 weeksUBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies. Guangdong, China and Bagsværd, Denmark, 24 February 2026 – The United Laboratori
About this update from Novo Nordisk A/s Class B
[{"type":"image","alt":"Novo Nordisk A/S","displaySize":"","headline":null,"caption":"Novo Nordisk A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":214,"url":"https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Sq36MpNFOiz.w6RiXrpsqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e","width":300,"height":214}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nordisk","length":148,"tagName":"p"}]},{"val":[{"type":"text","content":"In a placebo-controlled phase 2 trial in Chinese people with overweight or obesity, UBT251 led to a statistically significant mean weight loss of up to 19.7% after 24 weeks","length":172,"tagName":"p"}]},{"val":[{"type":"text","content":"UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies.","length":99,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":419,"olType":false},{"type":"text","content":"Guangdong, China and Bagsværd, Denmark, 24 February 2026 – The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) today announced topline results from a Chinese phase 2 trial of UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon (triple G).","length":302,"tagName":"p"},{"type":"text","content":"UBT251 is being jointly developed by TUL’s wholly-owned subsidiary The United Bio-Technology (Hengqin) Co., Ltd. (United Biotechnology) and Novo Nordisk under an agreement signed in March 2025. United Biotechnology is responsible for development in Chinese mainland, Hong Kong, Macau and Taiwan, while Novo Nordisk is responsible for development in the rest of the world.","length":371,"tagName":"p"},{"type":"text","content":"The trial, conducted by United Biotechnology, investigated the safety and efficacy of once-weekly injectable 2 mg, 4 mg and 6 mg doses of UBT251 compared to placebo in Chinese people with overweight or obesity. From a baseline mean body weight of 92.2 kg, the highest mean weight loss observed for people treated with UBT251 was 19.7% (-17.5 kg) compared t...